Signal Genetics has selected Pronto Diagnostics as the exclusive representative and distributor for Myeloma Prognostic Risk Signature (MyPRS) test in Israel.
Signal’s MyPRS test is performed at the company’s CLIA lab located in Little Rock, Arkansas.
Signal Genetics, the parent company of Myeloma Health, is a privately held predictive genetic testing company focused on helping cancer patients.
Tel Aviv-based Pronto Diagnostics provides services for molecular diagnosis of disease with a focus on oncology, including the development and distribution of genetic testing kits.
Pronto Diagnostics has similar distribution relationships with several molecular diagnostic companies including Ipsogen, Pathwork Diagnostics and Epigenomics.
Pronto diagnostics CTO and chairman Nir Navot said their agreement with Signal Genetics allows them to provide a valuable prognostic tool to Israeli hematologists who treat Myeloma patients, in line with their commitment to increasing personalization of treatment for cancer patients.